Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

OTHER 10NIH 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 4Tuberous Sclerosis 2Neoplasm Metastasis 2Myelodysplastic Syndromes 2Leukemia 2Hematologic Neoplasms 2Graft vs Host Disease 2Carcinoma, Non-Small-Cell Lung 2Advanced Solid Tumors 2Skin Neoplasms 1Recurrence 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Perivascular Epithelioid Cell Neoplasms 1Pancreatic Neoplasms 1Neoplasms 1Melanoma 1Malignant Solid Tumors 1Lymphoma, Non-Hodgkin 1Lymphoma, B-Cell 1Lymphoma 1Leukemia, Myeloid, Acute 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia, Biphenotypic, Acute 1Gastroenteropancreatic Neuroendocrine Tumors 1Fibroma 1Facies 1Exanthema 1Erythema 1Colorectal Neoplasms 1

Interventions

Dexamethasone 64Cyclophosphamide 35pomalidomide 34Lenalidomide 34Rituximab 31Bortezomib 30venetoclax 28fludarabine 27Gemcitabine 21carfilzomib 20Paclitaxel 19pembrolizumab 17daratumumab 17Cisplatin 16Carboplatin 15Calcium Dobesilate 14Azacitidine 14ibrutinib 12Docetaxel 12Cytarabine 12obinutuzumab 11Nivolumab 11durvalumab 10Injections 10Doxorubicin 10Bevacizumab 10selinexor 9cemiplimab 9blinatumomab 9Cetuximab 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Recurrence × Sirolimus × Clear all
NCT06743503 2025-09-18

UB-VV400 in Combination With Rapamycin in Relapsed or Refractory B-cell Malignancies

Nanjing IASO Biotechnology Co., Ltd.

Phase 1 Recruiting
70 enrolled

Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡